Abstract: This invention relates to compositions and methods for treatment of vascular conditions. The invention provides arginine polymers and arginine homopolymers for the treatment and/or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing. The invention also provides arginine polymers and arginine homopolymers for use in organ perfusate and preservation solutions.

Abstract: The present invention provides a method for producing an L-amino acid using a bacterium of the Enterobacteriaceae family, particularly a bacterium belonging to genus Escherichia or Pantoea, which has been modified to attenuate expression of the rspAB operon.

Abstract: Processes for producing a suitable purity grade of L-Citrulline are disclosed. The processes can include contacting crude L-Citrulline in an aqueous solution with an adsorptive medium at a temperature above approximately 50° C. and below the temperature of denaturement for the L-Citrulline for an interval sufficient to remove at least one contaminant from the L-Citrulline. The processes can also include concentrating the dissolved L-Citrulline relative to the aqueous solution.

Abstract: The present invention provides a polypeptide which has: (i) an amino acid sequence wherein one or more amino acid residues are substituted in the region at positions 20 to 38 from the N terminus of the amino acid sequence shown in SEQ ID NO: 1; or (ii) an amino acid sequence wherein one or more amino acid residues are substituted in the region at positions 20 to 38 from the N terminus of the amino acid sequence shown in SEQ ID NO: 1 and one or more amino acid residues are deleted, substituted or added in the region at positions 1 to 19 or 39 to 294; and which has N-acetylglutamate kinase activity.

Abstract: A bacterium belonging to the genus Escherichia which has an ability to produce an L-amino acid, wherein the ability to produce the L-amino acid is increased by increasing expression of the yggA gene is described. A method for producing the L-amino acid using the bacterium is also described.

Abstract: The present invention provides a method for producing an L-amino acid using a bacterium of the Enterobacteriaceae family, particularly a bacterium belonging to genus Escherichia or Pantoea, which has been modified to attenuate expression of a gene coding for sRNA.

Abstract: An L-amino acid is produced by culturing an L-amino acid-producing bacterium which belongs to the Enterobacteriaceae family and which has been modified so that the acetyl-CoA synthetase activity is increased.

Abstract: The present invention provides a method for producing an L-amino acid using a bacterium of the Enterobacteriaceae family, particularly a bacterium belonging to genus Escherichia or Pantoea, which has been modified to attenuate expression of the sfmACDFH-fimZ cluster and/or the fimZ gene.

Abstract: The present invention provides a method for producing an L-amino acid using a bacterium of the Enterobacteriaceae family, particularly a bacterium belonging to the genus Escherichia or Pantoea, which has been modified to attenuate expression of the bolA gene.

Abstract: The invention relates to a method for the production of L-amino acids by fermentation of recombinant microorganisms of the Enterobacteriaceae family, characterized in that a) the microorganisms producing the desired L-amino acid and wherein the lamB-gene or nucleotide sequence coding for the gene product maltoporin is amplified, particularly overexpressed, are cultivated in a medium in conditions enabling the desired L-amino acid to be enriched in the medium or in cells, and b) the desired L-amino acid is isolated, wherein constituents of the fermentation broth and/or biomass remain in the entirety thereof or in parts thereof (=0 bis 100%) in the isolated product or are fully removed.

Abstract: L-Glutamic acid, L-proline or L-arginine is produced by culturing a bacterium belonging to the genus Escherichia, which is L-isoleucine auxotrophic and has ability to produce L-glutamic acid, L-proline or L-arginine, in a medium containing L-isoleucine, to produce and accumulate L-glutamic acid, L-proline or L-arginine in a culture, and collecting L-glutamic acid, L-proline or L-arginine from the culture.

Abstract: The present invention relates to fermentation processes for the production of cyanophycin in a microorganism whereby a plant-derived nitrogen source is converted by the microorganism into cyanophycin. The plant-derived nitrogen source preferably is a process stream being obtained in the processing of agricultural crops such as e.g., a by-product in the processing of starch from agricultural crops like corn, potato or cassave. The invention further relates to processes for the conversion of cyanophycin into a variety of compounds including e.g., ornithine, 1,4-butanediamine, n-alkyl amino alcohols, acrylonitrile, as well as cyanophycin derived functionalised poly(aspartic acid)s wherein the arginine residues have been functionalised to ornithine, (N-L-arginino)succinate, N-phospho-L-arginine or agmantine and the lysine residues have been functionalised to N6-hydroxy-L-lysine, 2,5-diaminohexanoate, N6-(L-1,3-dicarboxypropyl), pentanediamine, 5-aminopentanamide or N6-acetyl-L-lysine.

Abstract: There is disclosed a method for producing an L-amino acid, for example L-threonine, L-lysine, L-histidine, L-phenylalanine, L-arginine, L-tryptophan or L-glutamic acid, using a bacterium of the Enterobacteriaceae family, wherein the bacterium has been modified to enhance an activity of L-arabinose permease.

Abstract: The present invention relates to methods for converting plant cell wall polysaccharides into one or more products, comprising: treating the plant cell wall polysaccharides with an effective amount of a spent whole fermentation broth of a recombinant microorganism, wherein the recombinant microorganism expresses one or more heterologous genes encoding enzymes which degrade or convert the plant cell wall polysaccharides into the one or more products.

Abstract: The present invention provides a polypeptide comprising an amino acid sequence in which at least one amino acid is deleted, substituted or added in an amino acid sequence of isopropylmalate isomerase derived from a microorganism belonging to coryneform bacteria, wherein a coryneform bacterium which produces the polypeptide comprising the amino acid sequence as the sole isopropylmalate isomerase exhibits a partial leucine requirement in a minimal medium; a DNA encoding the polypeptide, a recombinant DNA comprising the DNA, a microorganism transformed with the recombinant DNA, and a process for producing an L-amino acid using the microorganism.

Abstract: There is provided a method for producing L-threonine, L-valine, L-proline, L-leucine, L-methionine and L-arginine using a bacterium belonging to the genus Escherichia wherein the L-amino acid productivity of the bacterium is enhanced by enhancing the activities of the proteins coded by the b2682 and b2683 genes, or the protein coded by the b1242 or b3434 gene.

Abstract: In a method for producing an L-amino acid by culturing a microorganism having an ability to produce an L-amino acid in a medium to produce and accumulate the L-amino acid in the medium and collecting the L-amino acid from the medium, a Gram-negative bacterium having the Entner-Doudoroff pathway and modified so that 6-phosphogluconate dehydratase activity or 2-keto-3-deoxy-6-phosphogluconate aldolase activity, or activities of the both are enhanced is used as the microorganism.

Abstract: L-Arginine is produced by culturing a coryneform bacterium in which an arginine repressor involved in L-arginine biosynthesis is deleted by disrupting a gene coding for the repressor, and which has L-arginine producing ability in a medium to produce and accumulate L-arginine in the medium, and collecting the L-arginine from the medium.

Abstract: A DNA encoding a variant of a protein having a loop region and six hydrophobic helixes which is involved in excretion of L-lysine to outside of a cell is described, wherein the DNA encodes a mutant protein which does not contain the loop region that is present in the wild-type protein. The mutant protein facilitates excretion of L-lysine, L-arginine, or both to the outside of the cell of a methanol assimilating bacterium when the DNA is introduced into the bacterium. Specifically, lysE24 is introduced into a methanol assimilating bacterium such as Methylophilus bacteria which results in improved L-amino acid productivity, especially production of L-lysine and L-arginine.

Abstract: The invention relates to mutants and alleles of the gnd gene from coryneform bacteria coding for 6-phosphogluconate dehydrogenases which contain at position 329 or a comparable position of the amino acid sequence any amino acid other than L-valine, and to processes for the production of amino acids, preferably L-lysine and L-tryptophan, by fermentation using bacteria that contain these alleles.

Abstract: A DNA encoding a variant of a protein, the protein having a loop region and six hydrophobic helices and involved in secretion of L-lysine to the outside of a cell, wherein the DNA encodes a variant of a protein not containing the loop region and facilitates secretion of L-lysine, L-arginine or both of these L-amino acids to the outside of a methanol-assimilating bacterium when the DNA is introduced into the bacterium, specifically lysE24, is introduced into a Methylobacillus bacteria to improve L-amino acid productivity, especially L-lysine and L-arginine productivities.

Abstract: The present invention relates to a mutated pyruvate carboxylase gene from Corynebacterium. The mutant pyruvate carboxylase gene encodes a pyruvate carboxylase enzyme which is resistant to feedback inhibition from aspartic acid. The present invention also relates to a method of replacing the wild-type pyruvate carboxylase gene in Corynebacterium with this feedback-resistant pyruvate carboxylase gene. The present invention further relates to methods of the production of amino acids, preferably lysine, comprising the use of this mutant pyruvate carboxylase enzyme in microorganisms.

Abstract: A DNA fragment which encodes a polypeptide defined in the following (a) or (b), and a polypeptide defined in the following (c) or (d): (a) a polypeptide which has at least the amino acid sequence of the amino acid numbers 50 to 393 in SEQ ID NO: 2 shown in Sequence Listing, (b) a polypeptide which has at least the amino acid sequence of the amino acid numbers 50 to 393 in SEQ ID NO: 2 shown in Sequence Listing including substitution, deletion, insertion, addition, or inversion of one or several amino acids, and can constitute a protein having a carbamoyl-phosphate synthetase activity with a large subunit of carbamoyl-phosphate synthetase having the amino acid sequence of SEQ ID NO: 3, (c) a polypeptide which has the amino acid sequence of SEQ ID NO: 3 shown in Sequence Listing, (d) a polypeptide which has the amino acid sequence of SEQ ID NO: 3 shown in Sequence Listing including substitution, deletion, insertion, addition, or inversion of one or several amino acids, and can constitute a protein having a car

Abstract: The invention relates to novel compounds comprising a ubiquitination recognition element and a protein binding element. The invention also relates to the use of said compounds for modulating the level and/or activity of a target protein. The compounds are useful for the treatment of disease such as infections, inflammatory conditions, cancer and genetic diseases. The compounds are also useful as insecticides and herbicides.

Abstract: L-arginine is produced using a bacterium belonging to the genus Escherichia harboring a mutant N-acetylglutamate synthase in which the amino acid sequence corresponding to positions from 15 to 19 in a wild type N-acetylglutamate synthase is replaced with any one of amino acid sequences of SEQ ID NOS: 1 to 4, and feedback inhibition by L-arginine is desensitized.

Abstract: The present invention provides nucleotide sequences from Coryneform bacteria which code for the PtsI protein and a process for the fermentative preparation of amino acids using bacteria in which the ptsI gene is enhanced.

Abstract: L-Arginine is produced by culturing a coryneform bacterium in which an arginine repressor involved in L-arginine biosynthesis is deleted by disrupting a gene coding for the repressor, and which has L-arginine producing ability in a medium to produce and accumulate L-arginine in the medium, and collecting the L-arginine from the medium.

Abstract: The present invention relates to the processes of racemization and deprotection of special N-protected amino acids in the acylase/racemase system for the total conversion of special N-protected racemic amino acids into optically pure amino acids.

Abstract: The inventions relate to the field of medicine, veterinary and biotechnology and may be used for production of a drug for medical and veterinary purposes. A bacteriolytic complex, produced by the bacterium Lysobacter sp. XL1, has been proposed, which contains bacteriolytic enzymes (muramidase, muramoylalanineamidase, endopeptidase, a bacteriolytic enzyme with a molecular weight of about 22 kDa), protease, polysaccharide, and ballast components. The method of production of the bacteriolytic complex includes cultivation of the strain-producer on a nutrient medium containing glucose, peptone, yeast extract or yeast autolysate, phosphate salts of sodium and potassium, magnesium sulfate, potassium chloride, iron sulfate, and water.

Abstract: Arginine can be efficiently produced by cultivating Escherichia coli which has an ability to produce arginine and an ability to utilize acetate in a culture medium to produce and accumulate arginine in the medium, and collecting arginine from the medium.

Abstract: In a method for producing an L-amino acid by culturing a microorganism having an ability to produce an L-amino acid in a medium to produce and accumulate the L-amino acid in the medium and collecting the L-amino acid from the medium, a Gram-negative bacterium having the Entner-Doudoroff pathway and modified so that 6-phosphogluconate dehydratase activity or 2-keto-3-deoxy-6-phosphogluconate aldolase activity, or activities of the both are enhanced is used as the microorganism.

Abstract: This invention refers to new surface-active compounds derived from arginine of the mono and diacylglyceride type according to the general formula (I) designed to act as surface agents with antimicrobial activity. The variations in the activity will depend on the number of fatty chains and their length. The purification of the intermediate and final products is achieved by means of liquid/liquid, liquid/solid extractions, crystallizations, ion-exchange chromatography and reverse-phase HPLC.

Abstract: L-arginine, citrulline and pyrimidine derivatives including orotic acid, uridine, uridine 5?-monophosphate (UMP), cytidine and cytidine 5?-monophosphate (CMP) are produced using a bacterium belonging to the genus Escherichia harboring a mutant carbamoylphosphate synthetase in which the amino acid sequence corresponding to positions from 947 to 951 in a wild type carbamoylphosphate synthetase is replaced with any one of amino acid sequences of SEQ ID NOS: 1 to 9, and feedback inhibition by uridine 5?-monophosphate in the bacterium is desensitized.

Abstract: L-Glutamic acid, L-proline or L-arginine is produced by culturing a bacterium belonging to the genus Escherichia, which is L-isoleucine auxotrophic and has ability to produce L-glutamic acid, L-proline or L-arginine, in a medium containing L-isoleucine, to produce and accumulate L-glutamic acid, L-proline or L-arginine in a culture, and collecting L-glutamic acid, L-proline or L-arginine from the culture.

Abstract: The present invention relates to a microorganism having an L-arginine producing ability where the microorganism synthesizes L-arginine through the biosynthetic linear or cyclic pathway and contains a recombinant DNA containing the argJ gene encoding an enzyme having ornithine acetyltransferase activity.

Abstract: Arginine can be efficiently produced by cultivating Escherichia coli which has an ability to produce arginine and an ability to utilize acetate in a culture medium to produce and accumulate arginine in the medium, and collecting arginine from the medium.

Abstract: L-Glutamic acid, L-proline or L-arginine is produced by culturing a bacterium belonging to the genus Escherichia, which is L-isoleucine auxotrophic and has ability to produce L-glutamic acid, L-proline or L-arginine, in a medium containing L-isoleucine, to produce and accumulate L-glutamic acid, L-proline or L-arginine in a culture, and collecting L-glutamic acid, L-proline or L-arginine from the culture.

Abstract: Disclosed is a method of reducing photooxidation or air oxidation in susceptible materials such as food, plastics or pharmaceuticals comprising mixing the material with an antioxidation composition comprising at least one amino acid, at least one metal ion, and at least one carboxylic acid in an amount effective to reduce photooxidation in the material.

Abstract: The present invention relates to the processes of racemization and deprotection of special N-protected amino acids in the acylase/racemase system for the total conversion of special N-protected racemic amino acids into optically pure amino acids.

Abstract: A compound and method for using compound-D SEQ ID NO:1 to reduce injury associated with ischemia and reperfusion of mammalian organs such as the heart. The compound may be administered as part of a preconditioning strategy which reduces the extent of injury and improves organ function following cessation and restoration of blood flow. The compound may be used in preparation for planned ischemia or in a prophylactic manner in anticipation of further ischemic events.

Abstract: A gene coding for glutamate dehydrogenase is introduced into a microorganism having L-arginine producing ability to enhance intracellular glutamate dehydrogenase activity and thereby improve the L-arginine producing ability. The present invention provides an improved method for producing L-arginine and a microorganism used therefor.

Abstract: L-arginine is produced using a bacterium belonging to the genus Escherichia harboring a mutant N-acetylglutamate synthase in which the amino acid sequence corresponding to positions from 15 to 19 in a wild type N-acetylglutamate synthase is replaced with any one of amino acid sequences of SEQ ID NOS: 1 to 4, and feedback inhibition by L-arginine is desensitized.

Abstract: Disclosed is a coryneform bacterium having L-arginine-producing ability in which an activity of intracellular argininosuccinate synthase is enhanced, wherein the activity of intracellular argininosuccinate synthase is enhanced by, for example, increasing copy number of a gene which codes for an argininosuccinate synthase derived form a coryneform bacterium in the bacterial cell, or modifying an expression regulation sequence for the gene in the bacterial cell so that expression of the gene should be enhanced. L-Arginine is produced by culturing the bacterium having L-arginine-producing ability in a medium so that L-arginine should be produced and accumulated, and collecting the L-arginine from the medium. The present invention provides a coryneform bacterium of improved L-arginine-producing ability and an efficient method for producing L-arginine.

Abstract: A DNA fragment which encodes a polypeptide defined in the following (a) or (b), and a polypeptide defined in the following (c) or (d):

Abstract: A process is described for purifying an amino acid-containing solution by means of electrodialysis, wherein an amino acid-containing solution is employed which is obtained from the fermentation for producing at least one amino acid.

Abstract: This invention refers to new surface-active compounds derived from arginine of the mono and diacylglyceride type according to the general formula (I) designed to act as surface agents with antimicrobial activity. The variations in the activity will depend on the number of fatty chains and their length. The purification of the intermediate and final products is achieved by means of liquid/liquid, liquid/solid extractions, crystallizations, ion-exchange chromatography and reverse-phase HPLC.

Abstract: The present invention discloses: (i) a non-pathogenic probiotic microorganism and its probiotic/therapeutic uses; (ii) a formulation comprising an aqueous solution of a volatile fraction (VF) prepared from the extract of at least one plant derived material and its therapeutic uses; (iii) a process of manufacturing the formulation from the plant derived material; (iv) a probiotic composition comprising the non-pathogenic probiotic microorganism of the invention and/or other probiotic microorganism(s) and the formulation of the invention, and its probiotic/therapeutic uses; (v) a composition for industrial applications comprising the formulation of the invention and microorganism(s) of industrial applicability; and (vi) industrial processes and apparatuses in which the latter composition is used.

Abstract: The present invention relates to a microorganism having an L-arginine producing ability, said microorganism being a microorganism synthesizing L-arginine through the biosynthetic linear or cyclic pathway, and bearing a recombinant DNA comprising a gene argJ coding for an enzyme having an ornithine acetyltransferase activity.

Abstract: L-Arginine is produced by culturing a coryneform bacterium in which an arginine repressor involved in L-arginine biosynthesis is deleted by disrupting a gene coding for the repressor, and which has L-arginine producing ability in a medium to produce and accumulate L-arginine in the medium, and collecting the L-arginine from the medium.

Abstract: Arginine can be efficiently produced by cultivating Escherichia coli which has an ability to produce arginine and an ability to utilize acetate in a culture medium to produce and accumulate arginine in the medium, and collecting arginine from the medium.